Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-10-01
Col·lecció:	Cancer Medicine
Matèries:	anlotinib anti‐angiogenic non‐small cell lung cancer (NSCLC) PD‐1 sintilimab uncommon EGFR mutations
Accés en línia:	https://doi.org/10.1002/cam4.6548
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!